NCT06926582Not yet recruitingPhase 2
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Clinical Efficacy and Safety of HS-10374 in Adult Patients With Mild-to-moderate Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 13 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 305 (estimated)
- First submitted
- 10 Apr 2025
- Start date
- 9 Apr 2025
- Primary completion date
- 9 Jul 2026
- Lead sponsor
- Hansoh BioMedical R&D Company
- Diseases
- Psoriasis
- NCT number
- NCT06926582
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 305
- From 9 Apr 2025 to the primary completion date, 9 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of non-plaque psoriasis or drug-induced psoriasis
- Prior exposure to TYK2 inhibitors
- Have received the prohibited treatment during the protocol required washout period
Other illness
- Recent history of infection, history or risk of serious infection
- Any major illness or evidence of unstable condition of major organ systems including psychiatric disease
- Any condition possibly affecting the PK process of the study drug
- Evidence of other skin conditions that would interfere with the evaluation of psoriasis
- History of hypersensitivity to the ingredients of study drugs, history of anaphylaxis
Lab values
- Any significant laboratory or procedure abnormalities that might place the subject at unacceptable risk during this study period
Who the study is looking for
- Male or female subjects between the ages of 18-70 years
- Diagnosis of plaque psoriasis for at least 6 months
- sPGA score of 2-3, BSA 2-15%, PASI score 2-15
- Subject must be inadequately controlled with, or intolerant of at least one topical therapy
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Dermatology Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.